Fructose-fed hypertriglyceridemic rhesus monkeys dosed with volanesorsen (binding site 100% homologous)
“Because the binding site for volanesorsen is 100% homologous between rhesus monkey and human apoC-III mRNAs and lipid metabolism in nonhuman primates resembles that observed in humans, the effects of volanesorsen in rhesus monkeys that were made hypertriglyceridemic via administration of a high-fructose supplement were evaluated.”
Mouse and hamster apoC-III sequences diverge from human, so species-specific ASOs were used in rodent models
“Because of the divergence between the mouse, hamster and human apoC-III sequences, species-specific ASOs were employed in their respective in vivo evaluations.”
EMA: monkey PD study supportive of therapeutic benefit at the 300 mg dose and at reduced doses
“The PD study conducted in the monkey is supportive for a potential therapeutic benefit at 300 mg/kg as well as at a reduced dose level in case of thrombocytopenia.”